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Abstract 
 
Objectives 
Autoantibodies neutralising the effect of the bone regulatory cytokine osteoprotegerin 
(OPG) have been described in a patient with severe osteoporosis and coeliac disease. This 
study aimed to determine the prevalence and epitope specificity of autoantibodies to OPG 
in patients with coeliac disease, and correlate their presence with bone mineral density. 
 
Methods 
A direct enzyme linked immunosorbent assay was developed and used to screen patients 
with coeliac disease for autoantibodies to OPG. Recombinant fragments of OPG were 
made to evaluate the epitope specificity and affinity of these antibodies. Phenotype 
information of the patients was obtained by case note review. 
 
Results 
Raised titres of antibodies to OPG were found in 7/71 (9.8%) patients with coeliac 
disease, compared with 1/72 (1.4%) non-coeliac osteoporosis clinic control patients 
(p<0.05). Our results suggest a polyclonal antibody response to OPG is raised in these 
patients capable of recognising different epitopes of OPG with varying affinity. The titre 
of OPG antibodies was associated with lower bone mineral density Z score of the hip in 
coeliac patients on univariate (p<0.05) and multivariate analysis including age, sex height 
and weight as covariates (p<0.01). 
 
Conclusion 
Polyclonal antibodies to OPG are more common in patients with coeliac disease and are 
independently associated with lower bone mineral density Z scores of the hip. Further 
work is required to establish the clinical utility of testing for OPG antibodies.  
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1. Introduction 
Autoantibodies to endogenous cytokines are increasingly recognised as a cause of disease 
pathogenesis (1). Autoantibodies neutralising the bone regulatory cytokine 
osteoprotegerin (OPG) have previously been described in a patient with severe 
osteoporosis and an incidental finding of autoimmune thyroid and coeliac disease (2). 
OPG acts as a decoy receptor for the receptor activator of NFkB ligand (RANKL) leading 
to inhibition of osteoclast differentiation and reducing bone resorption (3-5). The 
importance of this pathway in bone metabolism is demonstrated by the fact that 
pharmacological blockade of RANKL is an effective treatment for osteoporosis (6) and 
that loss of function mutations of OPG in humans lead to raised bone turnover and 
multiple fractures in childhood (7).  
 
Whilst osteoporosis is a common complication of many autoimmune diseases it is 
typically attributed to disease specific factors or steroid treatment rather than a direct 
autoimmune process (8,9). In coeliac disease up to 20-50% of newly diagnosed patients 
have reduced bone density, which is usually attributed to associated malabsorption and 
secondary calcium and vitamin D deficiencies, or to gut inflammation and the release of 
pro-inflammatory cytokines, though the severity of osteoporosis often bears little relation 
to the severity of the underlying coeliac disease (9-12). A gluten-free diet, the only 
available treatment for coeliac patients, improves bone mass and, consequently, reduces 
fracture risk, although the co-administration of mineral active drugs may be useful in a 
subgroup of coeliac disease patients (13). In the index patient with neutralizing OPG 
antibodies the osteoporosis did not respond to a gluten free diet, though there was a 
remarkable normalisation of bone mineral density in response to inhibition of bone 
turnover with intravenous bisphosphonate therapy. Therefore OPG antibodies seem to be 
associated with the development of high bone turnover osteoporosis, but whether they 
commonly contribute to the pathogenesis of osteoporosis in patients with coeliac disease 
remains to be determined.  
 
In this study, we have developed an enzyme linked immunosorbent assay for 
osteoprotegerin antibodies using whole or partial recombinant OPG and used this to 
determine the prevalence and epitope specificity of OPG antibodies in a cohort of patients 
with coeliac disease.  
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2. Materials and Methods 
 
2.1 Subjects 
Subjects were recruited from coeliac disease or osteoporosis clinics in NHS Lothian with 
approval of the local ethics committee. Bone density in all patients was determined by 
dual X-ray absorptiometry using a Hologic QDR4500 densitometer. Since many of the 
patients were men under the age of 50, or premenopausal women, we report both the bone 
density Z score and T score in line with current recommendations(14). A total of 71 adult 
coeliac patients were included in the study (57/71 female (80%); median age 54 (range 
23 to 83 years, interquartile range (IQR) 19 years). 20 patients were within 2 years of 
diagnosis (median disease duration 2 months (range 7 days to 19 months, IQR 9 months) 
with 51 patients having disease duration > 2 years (median disease duration 13 years, 
range 2 to 45 years, IQR 9 yrs). All patients were diagnosed with coeliac disease by a 
gastroenterology consultant based on the detection of IgA anti-tissue transglutaminase 
antibodies in serum, and confirmed by a small intestinal biopsy. 17/71 coeliac patients 
(24%) had osteoporosis, 32/71 (45%) had osteopenia and 22/71 (31%) had normal bone 
density T scores.  72 control patients (60/72 female (82%), median age 70 (range 22 to 
93 years, IQR 17.5 years) were recruited when attending an osteoporosis clinic, and were 
confirmed to be negative for tissue transglutaminase antibodies on routine screening. 
41/72 (%) of the osteoporosis clinic patients were confirmed as having osteoporosis on 
their most recent bone density scan, 25/72 (35%) had osteopenia and 6/72 (8%) had 
normal bone density. A reference range for OPG antibodies was derived from 22 healthy 
volunteers with no known underlying disease.  
 
2.2 Recombinant human Osteoprotegerin cloning 
The coding sequence of human OPG was amplified from an IMAGE clone template 
(NCBI accession: BC030155.2, IMAGE: 4875170) with Q5 Hot Start High-Fidelity DNA 
Polymerase (New England Biolabs, Massachusetts, USA) using three pairs of primers 
designed to clone and express three fragments covering the entire OPG protein (Table 1). 
The forward primers include a BglII restriction site, and the reverses include the site for 
XhoI. The PCR products were digested with BglII and XhoI restriction endonucleases and 
purified before ligation into the expression vector pET32a (Novagen, Darmstadt, 
Germany). In this vector target genes are cloned under the control of a bacteriophage T7 
promoter and the resulting peptides are fused with the 109aa Trx•Tag™ thioredoxin 
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protein. The resulting recombinant plasmids were designated pET-OPG1, 2 and 3. The 
DNA sequences for all constructs were verified by enzyme digestion and DNA 
sequencing. 
 
2.3 Protein expression and purification 
The pET-OPG plasmids were transformed into Escherichia coli BL21 (DE3) RP 
competent cells for protein expression. The transformed cells were grown in Luria broth 
(LB) with 34 µg/ml chloramphenicol and 100 µg/ml ampicillin at 37 oC and protein 
expression was induced with a final concentration of 100 µM Isopropyl β-D-1-
thiogalactopyranoside (IPTG) once the OD600 had reached 0.6–0.8. The temperature was 
lowered to 25 oC and the bacterial cell culture was incubated for a further 6 h for protein 
expression. 
 
The cell pellet was harvested by centrifugation at 5000 rpm for 15 min at 4 oC. The cells 
were resuspended in 5 volumes of binding buffer (300 mM NaCl, 15 mM Imidazole, 50 
mM Tris-HCl pH 8, 10% Glycerol, 10 mM β-Mercaptoethanol, 250 µM Phenyl methyl 
sulfonyl fluoride) containing EDTA-free protease inhibitor tablet (Roche, Basel, 
Switzerland). After the cells were freeze-thawed twice on dry-ice, they were digested 
with 1 mg/ml Lysozyme for 30 min on ice. Cells were then extensively sonicated and the 
lysate was clarified by centrifugation at 16000 g at 4 oC for 30 min. The supernatant was 
mixed with 2 ml of Ni-NTA Agarose (Qiagen, Hilden, Germany), pre-washed in binding 
buffer, and incubated 1 h on a roller at room temperature (RT). The resin was centrifuged 
at 3000 x g for 5 min and washed three times by gentle inversion with 10 ml of wash 
buffer (binding buffer + 5 mM Imidazole). The suspension was transferred into a column 
with wash buffer and the flow-through was collected and loaded into the column a second 
time. The column was then washed three times with 10 ml of wash buffer, and protein 
was eluted with elution buffer (300 mM NaCl, 250 mM Imidazole, 50 mM Tris-HCl pH 
8, 250 µM Phenyl methyl sulfonyl fluoride (PMSF), 10 mM β-Mercaptoethanol). 1 ml 
fractions of eluate were collected from the column.  
 
2.4 SDS-PAGE and Western Blot analysis 
The eluted fractions were analyzed for yield and purity on sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE).  Protein samples were mixed with 2X 
SDS-PAGE loading buffer and boiled for 5 min at 100 °C; 10 µl of lysate, wash and 
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eluted fractions were analyzed. Separated proteins were Coomassie blue stained and the 
fractions containing protein were pooled and dialyzed overnight against TEN10P buffer 
(10 mM Tris-HCl pH 7.5, 1 mM EDTA, 10 mM NaCl, 250 µM PMSF, 0.05% NP40). 
Dialyzed protein was quantified by Qubit® 2.0 Fluorometer (Invitrogen, Paisley, UK) 
and stored in aliquots with 10% glycerol at -20 °C or analyzed by Western blotting.  
 
Separated proteins by SDS-PAGE were transferred to a polyvinylidene fluoride (PVDF) 
membrane. The PVDF membranes were incubated with anti-His monoclonal antibody 
(Sigma, Missouri, USA) or anti-OPG polyclonal antibody (Abcam, Cambridge, UK). 
After washing, horseradish peroxidase (HRP) conjugated anti-mouse or anti-rabbit IgG 
antibody (Jackson ImmunoResearch, Philadelphia, USA) was added. Immunoreactive 
protein bands were detected with the SuperSignal system (Pierce, Illinois, USA) 
according to the manufacturer’s instructions. 
 
2.5 Direct enzyme-linked immunosorbent assay (ELISA) 
Maxisorp microtiter plates (Greiner Bio-One, Frickenhausen, Germany) were coated with 
0.1 µg/well of OPG or partial recombinant OPG (R&D Systems, Minnesota, USA) in 0.2 
M of Na2CO3-NaHCO3 (pH 9.6), and incubated overnight at 4ºC. After the coating 
solution was removed, the wells were washed with phosphate-buffered saline (PBS) 
containing 0.05% Tween-20 (washing buffer) and blocked with blocking solution (PBS 
with 3% nonfat dry milk) for 1 hour at RT. Serum samples were diluted 1:1,000 in PBS-
3% bovine serum albumin (BSA) and added to the wells. After 1 h of incubation at RT, 
the plates were washed and HRP-conjugated goat anti-human IgG diluted 1:10,000 
(Jackson ImmunoResearch) was added. After 1 hour of incubation at RT, the plates were 
washed and 100 µL per well of substrate solution (TMB liquid substrate system, Sigma) 
was added. After incubation for 30 min at RT in the dark, color development was stopped 
with 100 µL per well of stop solution (KPL, Maryland, USA) and the absorbance was 
measured at 450 nm. Two separate assays were performed, each with two repetitions.  
 
2.6 Competitive enzyme-linked immunosorbent assay 
Maxisorp microtiter plates (Greiner Bio-One) were coated with 0.1 µg/well of OPG or 
partial recombinant OPG in 0.2 M of Na2CO3-NaHCO3 (pH 9.6), and incubated overnight 
at 4ºC. Plates were washed with washing buffer and blocked with blocking solution for 1 
hour at RT. Serial dilutions of OPG and partial recombinant OPG were made in PBS-
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3%BSA, to each of which was added the corresponding serum solution (1:1,000 in PBS-
3%BSA). The samples were pre-incubated 2 hour at RT with gentle mixing and then 
added to the wells. After 1 h of incubation at RT, the plates were washed and incubated 
for 1 hour at RT with anti-human IgG-HRP 1:10,000. Plates were washed again and the 
substrate solution was added. The reaction was stopped after dark incubation for 30 min 
at RT and the absorbance at 450 nm was measured. Two separate assays were performed, 
each with two repetitions.  
 
2.7 Statistical analysis  
Direct ELISA. All serum samples represent the mean of duplicate assays conducted on 
two different days, with a coefficient of variation of 12% between assays, and 6% within 
assays noted. A reference (antigen without serum) was included in each assay. Positive 
samples were defined a priori to be greater than the mean of healthy controls plus 2 
standard deviations (SD) which would be expected to define approximately 95% of a 
normal population. Statistical analysis was performed with the software package Minitab 
16.2.4 (Minitab Inc., State College PA, USA). The differences between groups were 
examined by Mann-Whitney U test for absolute OPG antibody readings (samples not 
normally distributed), and Fishers Exact test for categorical analyses of positive or 
negative samples. General regression analysis was performed in Minitab specifying bone 
mineral density as the response, with age, height, weight and OPG antibody titre entered 
as continuous variables, and sex as a categorical variable. The significance, regression 
coefficient and 95% confidence intervals for the regression coefficient are reported. 
 
Competitive ELISA. The OPG and partial recombinant OPG curves were obtained by 
plotting percentage maximum absorbance against logarithm of protein concentration. The 
Sigma Plot 11.0 program (Systat Software) was used to calculate IC50 and the cross-
reactivity (CR) for the protein or fragments. The IC50 is defined as the concentration that 
produces a reduction of 50% in the peak signal in the ELISA. The CR was determined as 
(IC50 of the protein or fragment that presents the greatest affinity for antibodies/IC50 of 
each protein or fragment assayed) x 100.  
 
3. Results 
 
3.1 Prevalence of autoantibodies against osteoprotegerin in coeliac patients 
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OPG antibody levels were determined by direct ELISA in serum samples from 71 patients 
with coeliac disease and 72 non-coeliac osteoporosis clinic controls (Figure 1A). A 
skewed distribution was observed with an excess of both elevated and low 
level/undetectable results obtained. Defining high titre positivity for OPG antibodies 
arbitrarily as having a value greater than the mean plus 2 SD of healthy subjects (0.56) 
gives a prevalence of 7/71 (9.8%) in coeliac patients, compared to 1/72 (1.4%) in the 
control cohort (p<0.05, Fishers Exact, two sided).  Conversely among the coeliac patients 
just 2/71 (2.8%) had undetectable levels of OPG antibody compared to 20/72 (27.8%) in 
the osteoporosis controls (p<0.001, Fishers Exact, two sided). These results suggest that 
OPG antibodies are significantly more common in coeliac patients than in the non-coeliac 
osteoporosis clinic controls. Similarly the median OPG antibody level by direct ELISA 
in coeliac patients was 0.09 units (Interquartile range (IQR) 0.16), and in osteoporosis 
clinic controls 0.02 units (IQR range 0.06) (p<0.001 Mann-Whitney U test). No 
significant difference in the antibody titre was observed between patients within 2 years 
of diagnosis or those > 2 years from diagnosis (p=0.47 Mann-Whitney U test). 
 
A summary of the characteristics of patients with raised OPG antibody titres is given in 
Table 2 though we acknowledge that the small sample size in this study limits the 
conclusions that it is possible to draw. No significant difference between the groups in 
terms of conventional risk factors for osteoporosis is seen and similarly no significant 
difference was observed in the small number of patients reporting steroid exposure (n=2) 
or concomitant autoimmune disease (n=3). Patients with raised OPG antibody levels had 
lower BMD T and Z scores though this did not reach statistical significance in a case 
control analysis (p values represent 2 sided student T-test for continuous variables or 
Fishers Exact test for categorical variables). This trend is not contributed to by treatment 
effects since a greater proportion of patients with raised OPG antibodies were receiving 
anti-resorptive therapy. In a univariate regression analysis the titre of OPG antibody is 
significantly associated with total hip BMD Z score (p=0.039, regression coefficient -
0.49 [-0.94 - -0.03]) (Figure 1B) but not spine BMD Z score (p=0.49, regression 
coefficient -0.21 [-0.80 - 0.39]). Multivariate regression analysis including age, sex, 
height and weight as covariates strengthens the association of OPG antibody titre with 
total hip BMD Z score (p<0.01, regression coefficient -0.58 [-0.99 - -0.17]) though spine 
BMD Z score remains not significant (p=0.33, regression coefficient -0.27 [-0.84 - 0.29]). 
Within the control cohort no association between titre of antibody and bone density was 
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observed. An arbitrary threshold of mean plus 2 standard deviations of levels seen in 
healthy controls does not identify a population that is more likely to have osteoporosis, 
though we did observe that the two patients within this group with the highest titre of 
antibody were both osteoporotic. These results are compatible with a role for OPG 
antibodies in the pathogenesis of osteoporosis in a small number of patients with coeliac 
disease though must be interpreted with caution in view of the small sample size. 
 
3.2 Expression and purification of Osteoprotegerin recombinant fragments  
With the aim of evaluating the epitope specificity of OPG antibodies three pairs of 
primers were used to amplify and clone three different peptide fragments covering the 
full OPG protein (Table 1). These primers were designed on the basis of the OPG 
structure which consists of 7 structural domains (Figure 2A). The recombinant plasmids 
pET-OPG1 and pET-OPG2 express the amino-terminal cysteine rich domains (D1-D4) 
which are necessary for binding to RANKL (15,16). The third recombinant plasmid, pET-
OPG3, was designed to express the carboxy-terminal portion of the protein that contains 
two putative death domain homologous regions (D5 and D6) which have been related to 
cytotoxic signals in mammalian cells (15,17), and a heparin-binding region (D7). To 
verify protein expression we analyzed the whole cell extract by anti-His monoclonal 
antibody (moAb) immunoblotting. The E. coli cultures transformed with pET-OPG1 and 
pET-OPG2 expressed the OPG fragments with the size expected (Figure 2B), however 
the cell extract from pET-OPG3 cultures showed lots of degradation products (data not 
shown). These results suggested the carboxy-terminal region interferes with the survival 
of E. coli cells and leads to bacteria death or promotes significant defects in bacteria 
growth that dramatically decrease expression capabilities. Therefore, this region could 
not be expressed in E. coli cultures.  
 
In order to confirm the correct expression of pET-OPG1 and pET-OPG2 plasmids, 
another antibody specific for the OPG protein was used to analyze the different fragments 
(Figure 2C). The results obtained with anti-OPG polyclonal antibody (pAb) demonstrate 
that this antibody was able to detect the same protein fragments as the anti-His moAb. At 
the same time, these results confirmed the correct expression of OPG recombinant 
fragments.  
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The recombinant partial proteins (OPG1 and OPG2) contain a His tag, therefore, Ni-NTA 
agarose (Qiagen) was used to purify them. The eluted fractions were almost entirely free 
of contaminating proteins as visualized by Coomassie staining (Figure 3A). To confirm 
these results with specific antibodies against fragments of interest, the positive fractions 
eluted were pooled and immunoblotting electrophoresis analyses were performed. As 
shown in figure 3B, anti-His moAb and anti-OPG pAb had affinity for a single band in 
the pooled eluate. Altogether, these results verified the expression and purification 
process of the OPG recombinant fragments. 
 
3.3 Epitope specificity of OPG antibodies 
To evaluate the antibody response and the epitope specificity, positive coeliac sera for 
OPG antibodies were selected. Thus, six serum samples were chosen (Coe05, Coe17, 
Coe18, Coe58, Coe59 and Coe66). The sera reactivity was determined by direct ELISA 
using the partial recombinant OPG (OPG1 or OPG2). All serum samples were able to 
recognize both fragments (Figure 4). Antibodies present in the different sera showed 
different affinity toward OPG1 and OPG2, although this variability was not statistically 
significant. The tendency observed towards a higher affinity for OPG1 might be due to a 
greater number of epitopes or more reactive epitopes in this region. In any case these 
results suggest that the autoantibodies are recognising diverse epitopes throughout the 
OPG sequence.  
 
In order to quantify the relative affinity of antibodies for OPG fragments, two sera were 
selected based on their reactivity against OPG, Coe05 and Coe17. A third serum, from 
the patient where antibodies were described for first time (2), was included as a control. 
The antibodies’ affinity was determined by competitive ELISA and the IC50 and CR were 
determined for each serum. As shown in figure 5A, Coe05 presented similar IC50 value 
for OPG1 and OPG2 (1.45 and 1.44 µg/ml, respectively), showing comparable reactivity 
for both fragments. The control serum presented the greatest affinity for OPG1 (IC50=0.58 
µg/ml) and OPG2 (IC50=0.88 µg/ml). The serum Coe17 showed the least affinity for the 
fragments with CR of ~30% with respect to the most reactive serum. These data showed 
a range of reactivity, being consistent with previously obtained results by direct ELISA. 
To analyse if this variability of fragments reactivity is translated in different affinity 
towards the protein, a competitive ELISA with whole OPG was performed. The Coe05 
serum presented an intermediate reactivity with an IC50 of 3.17 µg/ml, with the control 
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serum again the most reactive for the full protein (IC50=0.002 µg/ml) (Figure 5B). 
Surprisingly the least reactive serum for OPG1 and OPG2, Coe17, did not show any 
affinity for whole OPG (IC50 not applicable). It is possible that this serum recognises a 
cryptic epitope on OPG that is revealed on OPG fragments, but is masked in whole OPG 
in solution, so being able to bind to the protein in direct ELISA but not in competition 
assays. Overall the wide range of epitopes recognised and affinities demonstrated 
indicates a polyclonal antibody response that differs between distinct subjects.   
 
4. Discussion 
Naturally occurring self-reactive autoantibodies have long been recognized, though their 
role in normal physiology, as well as in disease pathogenesis, is the subject of ongoing 
research (1,18,19). We have previously described a case of severe osteoporosis in a 
patient with coeliac disease that occurred in association with the development of 
autoantibodies to OPG that were identified using an immunoprecipitation assay (2). This  
assay is unsuitable for population screening and we note that no significant results were 
found in a small cohort of 30 coeliac patients screened using this method (20). The current 
study employed a sensitive and robust enzyme linked immunosorbent assay to detect 
osteoprotegerin antibodies and identified raised titres of OPG antibody in 7/71 (9.8%) 
patients with coeliac disease when compared to 1/72 (1.4%) in a control cohort of patients 
attending an osteoporosis clinic. The threshold used to define a positive test is essentially 
arbitrary and does not imply any clinical significance in these patients. A significantly 
lower level of undetectable antibodies found in just 2/71 (2.8%) coeliac patients, 
compared to 20/72 (27.8%) in the controls is again consistent with this tendency to 
autoantibody generation in patients with coeliac disease. These results suggest that it is 
the coeliac disease that drives the generation of the autoantibody response to OPG rather 
than such antibodies being a consequence of bone disease itself.  It is not possible to 
conclude from our data whether this association relates to the known genetic 
predisposition to autoimmunity in patients with coeliac disease, or is a direct consequence 
of coeliac disease (21). Specifically within this cohort we found no correlation with the 
level of tissue transglutaminase antibody and OPG antibody. We note that OPG 
antibodies have also been identified in a cohort of patients with rheumatoid arthritis(22). 
 
A significant correlation between OPG antibody titre and hip bone density Z-score is 
observed, and persists on multivariate analysis including age, sex, height and weight, 
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compatible with a pathogenic role for OPG antibodies in a proportion of these patients. 
No significant correlation was observed between OPG antibody titre and spine bone 
density however, and we acknowledge that the clinical significance of OPG antibodies 
has not been established by this data, and that this will need further investigation in a 
larger cohort. 
 
Studies with recombinant OPG fragments suggested that the autoantibodies generated 
against whole osteoprotegerin recognise epitopes within distinct regions of the protein, 
and with widely differing affinities, in keeping with a polyclonal antibody response. The 
ELISA that we have developed is a useful screening tool for the presence of such 
antibodies, however both the affinity and epitope specificity of autoantibodies will be 
important determinants of antibody function. Consistent with this we note that significant 
functional inhibition of OPG was demonstrated by only 3 out of 6 positive samples for 
OPG antibodies recently identified using a similar ELISA methodology(22). Serum from 
the index case was associated with the greatest affinity for both whole OPG and the partial 
OPG fragments in this study which will in part explain the dramatic phenotype seen. The 
large ~100 amino acid fragments of OPG that were used in the current experiments were 
unable to detect any differential epitope specificity in the serum samples analysed, 
therefore further work with smaller fragments could be useful to fine map these responses. 
 
5. Conclusion 
A polyclonal autoantibody response to OPG is identified in patients with coeliac disease. 
A significant association of OPG antibody titre with lower total hip bone mineral density 
is compatible with a pathogenic role of OPG antibodies in a subset of these patients, 
though further work is required to replicate this finding and to establish the clinical utility 
of testing for OPG antibodies. 
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Tables 
 
Table 1. PCR primers used for clone and express three fragments covering the entire 
OPG protein. 
Primer Description  Sequence (5’-3’) 
F1-F Forward primer for 
fragment 1 
CCCAGATCTGATGAACAACTTGCTGTGCTGC 
F1-R Reverse primer for 
fragment 1 
GGTGCTCGAGTTAGTTGTGGGTGCGATTGC 
F2-F Forward primer for 
fragment 2 
CCCAGATCTGCGCGTGTGCGAATGCAAGG 
F2-R Reverse primer for 
fragment 2 
GGTGCTCGAGTTAGAAGAATGCCTCCTCACAC 
F3-F Forward primer for 
fragment 3 
CCCAGATCTGAGGTTTGCTGTTCCTACAAAG 
F3-R Reverse primer for 
fragment 3 
GGTGCTCGAGTTATAAGCAGCTTATTTTTAC 
 
Table 2. Characteristics of coeliac patients with high titre OPG antibodies 
Variable Raised OPG Ab (n=7) Normal OPG Ab 
(n=64) 
p value 
Age 56.8 (±12.9) 60.4 (±14.6) 0.54 
Female gender 5/7 (71.4%) 52/64 (81.2%) 0.62 
BMI 28.2 (±11.6) 25.5 (±4.5) 0.24 
Alendronate use 3/7 (42%) 10/64 (15%) 0.11 
Duration of 
disease (months) 
141 (±161) 120 (±115) 0.66 
Prior fragility 
fracture 
3/7 (42.9%) 21/64 (32.8%) 0.68 
Spine T-score -1.61 (±1.33) -1.36 (±1.25) 0.61 
Spine Z-score -0.44 (±1.47) - 0.19(±1.08) 0.58 
Tot Hip T-score - 1.15(±0.96) - 0.65(±0.99) 0.20 
Tot Hip Z-score -0.54 (±1.26) 0.125 (±0.83) 0.06 
Osteoporosis 
status 
Osteoporosis 2/7 
(28.6%) 
Osteopenia 2/7 (28.6%) 
Normal 3/7 (42.8%) 
Osteoporosis 15/64 
(23.4%) 
Osteopenia 17 (26.6%) 
Normal 22/64 (34.3%) 
1.0 
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Figures 
 
Figure 1. Detection of antibodies against OPG. A. Levels of OPG antibodies in coeliac 
and non-coeliac patients. Each point represents the mean absorbance – reference value of 
one patient at OD 450 nm. The threshold for a positive sample is defined as the mean of 
healthy controls plus 2 standard deviations and illustrated as a horizontal dotted line. B. 
Regression analysis of OPG antibody levels against total hip bone mineral density Z-
score. 
 
 
Figure 2. Expression of OPG recombinant fragments. A. Osteoprotegerin protein 
structure. The different fragments cloned and expressed are shown. B. Western blot 
analysis of whole cell extract. Membranes were incubated with anti-His moAb. C. 
Western blot analysis of whole cell extract. Membranes were incubated with anti-OPG 
pAb. In B and C, lane 1 and 2 are extract of pET-OPG1 and pET-OPG2 respectively. 
Protein size markers (kDa) are indicated on the left. 
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Figure 3. Purification of OPG recombinant fragments. A. Coomassie blue staining of 
OPG1 and OPG2 purification. Ten microliters of lysate, wash and eluted fractions was 
analyzed. B. Western blot analysis of fractions pooled by OPG pAb (pOPG) and His 
moAb (moHis). In A and B, protein size markers (kDa) are indicated on the left. 
 
Figure 4. Reactivity of OPG antibodies towards OPG recombinant fragments. Each 
bar represents the mean absorbance – reference value ± SD of each serum at OD 450 nm. 
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Figure 5. Epitope specificity of OPG antibodies. A. Competitive ELISA to determine 
the relative affinity of OPG antibodies for the OPG recombinant fragments. IC50 and CR 
values of each serum to fragments are indicated. ●, Control; ▲, Coe05; ■, Coe17. B. 
Competitive ELISA to determine the relative affinity of OPG antibodies for OPG. The 
symbols code is the same as in A.  
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